Unsere Publikationen

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

Link
https://doi.org/10.1007/s40263-018-0586-5
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J; ENHANCE study investigators.
Verlag
CNS Drugs. 2019 Jan;33(1):61-79.
Zum Eintrag

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

Link
https://doi.org/10.3389/fneur.2019.00253
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV.
Verlag
Front Neurol. 2019 Mar 22;10:253.
Zum Eintrag

Tetrahydrocannabinol - cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence

Link
https://doi.org/10.2217/nmt-2018-0048
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Ziemssen T.
Verlag
Neurodegener Dis Manag 2019;9(2):1-2
Zum Eintrag

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany

Link
https://doi.org/10.1212/nxi.0000000000000548
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Couto CA, Findlay JA, Cornelissen C; PANGAEA study group.
Verlag
Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e548.
Zum Eintrag

Response to: Kobayashi et al.: “Erythroblast appearance associated with natalizumab” Multiple Sclerosis and Related Disorders 2019

Link
https://doi.org/10.1016/j.msard.2019.05.003
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Akgün K, Bornhäuser M, Ziemssen T.
Verlag
Mult Scler Relat Disord 2019;32:114-115.
Zum Eintrag

Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients

Link
https://doi.org/10.1177/2045894019872192
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Lerche M, Eichstaedt CA, Hinderhofer K, Grünig E, Tausche K, Ziemssen T, Halank M, Wirtz H, Seyfarth HJ.
Verlag
Pulm Circ. 2019 Nov 18;9(3):2045894019872192.
Zum Eintrag

Early central vs. peripheral immunological and neurobiological effects of fingolimod—a longitudinal study

Link
https://doi.org/10.1007/s00109-019-01812-x
Tags
Multiple SkleroseMS Behandlung
Jahr
2019
Autoren
Sehr T, Akgün K, Proschmann U, Bucki R, Zendzian-Piotrowska M, Ziemssen T.
Verlag
J Mol Med 2019;97(9):1263-1271.
Zum Eintrag

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

Link
https://doi.org/10.1007/s13311-017-0595-y
Tags
Multiple SkleroseMS Behandlung
Jahr
2018
Autoren
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Medin J, Cornelissen C; PANGAEA study group.
Verlag
Neurotherapeutics. 2018 Jan;15(1):190-199.
Zum Eintrag
8 9 10 11 12

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-